Literature DB >> 14576138

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Eric Dannaoui1, Jacques F G M Meis, David Loebenberg, Paul E Verweij.   

Abstract

Three isolates of zygomycetes were used to produce a disseminated infection in nonimmunocompromised mice. Against all zygomycete strains, amphotericin B significantly prolonged survival. Itraconazole was inactive against Rhizopus microsporus and Rhizopus oryzae but was partially active against Absidia corymbifera. Posaconazole had no beneficial effects against R. oryzae but showed partial activity against A. corymbifera. Posaconazole had a clear dose-response effect against R. microsporus.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14576138      PMCID： PMC253802          DOI： 10.1128/AAC.47.11.3647-3650.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.

Authors:  F C Odds; F Van Gerven; A Espinel-Ingroff; M S Bartlett; M A Ghannoum; M V Lancaster; M A Pfaller; J H Rex; M G Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

2.  In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.

Authors:  J E Lutz; K V Clemons; B H Aristizabal; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.

Authors:  L Z Goldani; A M Sugar
Journal:  J Antimicrob Chemother       Date:  1994-02       Impact factor: 5.790

5.  In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  J N Galgiani; M L Lewis
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

7.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).

Authors:  J Van Cutsem; J R Boelaert
Journal:  Kidney Int       Date:  1989-12       Impact factor: 10.612

9.  Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B.

Authors:  J Van Cutsem; F Van Gerven; J Fransen; P A Janssen
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

10.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  47 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

2.  Gastrointestinal zygomycosis complicating heart and lung transplantation in a patient with Eisenmenger's syndrome.

Authors:  Pavan Manchikalapati; Cheri L Canon; Nirag Jhala; Mohamad A Eloubeidi
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

3.  Rapid susceptibility testing of medically important zygomycetes by XTT assay.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Emmanuel Roilides; Tin Sein; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

4.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Authors:  Nikolaos G Almyroudis; Deanna A Sutton; Annette W Fothergill; Michael G Rinaldi; Shimon Kusne
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

6.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

7.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

8.  Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

Authors:  Susanne Perkhofer; Maria Locher; Manuel Cuenca-Estrella; Reinhard Rüchel; Reinhard Würzner; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

9.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

10.  Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Authors:  Dounia Bitar; Dieter Van Cauteren; Fanny Lanternier; Eric Dannaoui; Didier Che; Francoise Dromer; Jean Claude Desenclos; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.